Logos Global Management’s Dyne Therapeutics DYN Stock Holding History

Logos Global Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.4M	Buy	1,400,000 +150,000	+12%	+$2.59M	1.27%	28
2025 Q4	$24.4M	Sell	1,250,000 -1,150,000	-48%	-$21.8M	1.48%	24
2025 Q3	$30.4M	Buy	2,400,000 +500,000	+26%	+$5.7M	2.72%	14
2025 Q2	$18.1M	Buy	1,900,000 +1,400,000	+280%	+$15.4M	2%	17
2025 Q1	$5.23M	Buy	500,000 +50,000	+11%	+$715K	0.93%	25
2024 Q4	$10.6M	Buy	450,000 +290,000	+181%	+$8.58M	1.24%	29
2024 Q3	$5.75M	Sell	160,000 -105,000	-40%	-$4.18M	0.62%	37
2024 Q2	$9.35M	Sell	265,000 -1,465,000	-85%	-$42.6M	0.75%	35
2024 Q1	$49.1M	Sell	1,730,000 -150,000	-8%	-$3.39M	3.98%	9
2023 Q4	$25M	Sell	1,880,000 -300,000	-14%	-$2.93M	2.33%	15
2023 Q3	$19.5M	Buy	2,180,000 +400,000	+22%	+$4.31M	2.61%	13
2023 Q2	$20M	Buy	1,780,000 +80,000	+5%	+$944K	2.72%	14
2023 Q1	$19.6M	Sell	1,700,000 -450,000	-21%	-$5.84M	2.8%	13
2022 Q4	$24.9M	Sell	2,150,000 -137,321	-6%	-$1.59M	2.92%	15
2022 Q3	$29M	Sell	2,287,321 -612,679	-21%	-$7.02M	3.57%	11
2022 Q2	$19.9M	Buy	2,900,000 +165,608	+6%	+$1.14M	3.66%	12
2022 Q1	$26.4M	Sell	2,734,392 -500,000	-15%	-$4.26M	3.42%	16
2021 Q4	$38.5M	Sell	3,234,392 -385,000	-11%	-$5.41M	3.97%	8
2021 Q3	$58.8M	Buy	3,619,392 +1,565,000	+76%	+$27.7M	4.24%	5
2021 Q2	$43.2M	Sell	2,054,392 -1,150,000	-36%	-$21.6M	3.63%	5
2021 Q1	$49.8M	Buy	3,204,392 +1,600,000	+100%	+$31M	4.86%	4
2020 Q4	$33.7M	Hold	1,604,392	–	–	2.89%	6
2020 Q3	$32.4M	Buy	+1,604,392	New	+$35.2M	4.15%	8

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Logos Global Management's DYN Position: Q1 2026 in Review

Logos Global Management increased its Dyne Therapeutics (DYN) stake by 12% in Q1 2026, buying an estimated $2.59M and bringing the position to 1,400,000 shares worth $25.4M. The position accounts for 1.27% of the portfolio, ranked #28.

Logos Global Management first reported a position in DYN in Q3 2020 and has held it in 23 quarters since. The position peaked at $58.8M in Q3 2021. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Logos Global Management held 1,400,000 shares of Dyne Therapeutics worth $25.4M as of Q1 2026.
Logos Global Management bought 150,000 Dyne Therapeutics shares in Q1 2026, an estimated $2.59M.
Dyne Therapeutics made up 1.27% of Logos Global Management's portfolio in Q1 2026, its #28 holding.
Logos Global Management first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 23 quarters since.
Logos Global Management's Dyne Therapeutics position peaked at $58.8M in Q3 2021.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.